Adial Pharmaceuticals Announces International Patent Application for AD04
Adial Pharmaceuticals announced the publication of the international patent application for AD04, filed in July 2024. AD04 is the Company's lead investigational genetically targeted serotonin-3 receptor antagonist therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients. The patent, once granted, is expected to protect Adial's core assets through at least 2045. Cary Claiborne, President and Chief Executive Officer of Adial, commented, "As we continue to advance the AD04 program with planning for the next phase of our clinical program, the new patent application and its expected approval will extend protection of the core assets of Adial out to at least 2045. This application is the result of an extensive examination of data and information which occurred after Adial hired new patent counsel to bolster and leverage Adial's intellectual property portfolio."
Get Free Real-Time Notifications for Any Stock
Analyst Views on ADIL
About ADIL
About the author
Adial Pharmaceuticals Enters Warrant Inducement Agreement, Raising $2.86 Million
- Financing Agreement Reached: Adial Pharmaceuticals has entered into a warrant inducement agreement with an existing institutional investor, enabling the immediate exercise of existing Series C-1 Warrants to raise approximately $2.86 million, enhancing the company's liquidity to support R&D and operations.
- Warrant Details: The investor will receive new unregistered Series F Warrants to purchase up to 13,823,512 shares of Common Stock at an exercise price of $0.31, which will expire 24 months after shareholder approval, further enhancing the company's capital structure flexibility.
- Market Reaction Anticipated: This financing is expected to provide Adial with essential funding to advance its research in addiction treatment, particularly for its investigational drug AD04 targeting Alcohol Use Disorder, potentially boosting future market performance.
- Transaction Timeline: The closing of this transaction is expected around December 1, 2025, subject to customary closing conditions, demonstrating the company's proactive and strategic approach in capital market operations.
Adial Pharmaceuticals Announces Financial Results for Q3 2025 and Offers Business Update
Business Update: Adial Pharmaceuticals reported progress towards FDA approval for its lead drug AD04, aimed at treating Alcohol Use Disorder (AUD), following a successful End of Phase 2 meeting with the FDA that provided guidance for the upcoming Phase 3 study.
Legislative Support: Recent bipartisan support from the U.S. Senate encourages the expansion of clinical trial endpoints beyond abstinence, aligning with Adial's focus on reducing alcohol consumption and cravings, which reinforces their patient-centered treatment approach.
Partnership and Testing: Adial has partnered with Genomind to develop a precision medicine testing solution, completing validation for a genetic test that identifies eligible patients, which is crucial for clinical trials and future commercial use.
Financial Overview: As of September 30, 2025, Adial reported $4.6 million in cash, with a net loss of $1.8 million for the quarter, reflecting a decrease in research and development expenses compared to the previous year.
